Summary and conclusions Serum concentrations of anti-acetylcholine-receptor (anti-AChR) antibody were measured in patients with myasthenia gravis. In those patients undergoing thymectomy concentrations were measured before and after the operation to see whether there might be a connection between the thymus and antibody production. We found no correlation between antibody concentration and either thymectomy or duration and severity of the disease before the operation.
Introduction
Immunisation of animals with purified acetylcholine receptor (AChR) produces weakness and a disorder of neuromuscular transmission resembling human myasthenia gravis.' 2 Animals with this disorder, termed experimental autoimmune myasthenia gravis (EAMG),' develop antibodies to AChR. Similar antibodies have been found in the sera of 8700 of patients with myasthenia gravis3 and bound to AChR in the muscles of both patients4 and animals5 with myasthenia gravis. Although loss of AChR from muscle4 67 due to antibody-dependent mech- anisms -12 appears to be the most important factor in impairing neuromuscular transmission in myasthenia gravis and EAMG, the concentrations of antibody in the sera and the duration and severity of the disease are not closely correlated in groups of patients.3 Nevertheless, a decrease in antibody titre with a concomitant improvement in clinical state has been reported in serial studies of patients treated with plasmapheresis and immunosuppressive drugs.'3 14 Scadding et al"5 reported that anti-AChR antibody concentrations in patients with myasthenia gravis decreased with time after thymectomy.
We carried out a study of patients with myasthenia gravis in which we compared antibody concentrations in individual patients before and after thymectomy and in patients with and without thymectomy. We also analysed concentrations at various times after thymectomy and in relation to the duration of the disease.
Patients, methods, and results
All patients who took part in the study were diagnosed as having myasthenia gravis by their physician and in an independent review of their clinical history by one of us (MES). Almost all patients had a positive response to edrophonium or a decreasing response to repeated nerve stimulation, or both. Serum anti-AChR antibody titres were measured by radioimmunoassay, human AChR being used as the antigen. '6 We studied 26 patients before and after thymectomy. two years nine months postoperatively (mean 17 6 weeks, median 21 days). Figure 2 shows the titres obtained before and after thymectomy. When comparison of paired observations was made with the t test no significant difference was found between these titres (t = 0-858, DF=25, P >0 05 titres were found between any of the groups (P -0-05). Titres in both groups of patients who underwent thymectomy were obtained from one day to 14 years after the operation (patients with thymoma: mean 5-8 years, median 4-5 years; patients without thymoma: mean 5-2 years, median 2-1 years). Titres were obtained after thymectomy in 88 patients. The time after operation ranged from three months to 23 years (mean 6-5 years, median 5 7 years), and when several titres were available the most recent one was used in the analysis. Using the Spearman rank order correlation coefficient we found no change in titres with time after thymectomy (t = 1 0162, DF = 86, correlation = -0-1089). The same method was used to compare the titre after thymectomy with the duration of myasthenia gravis before thymectomy. No significant correlation was found (t=0 1589, DF=85, correlation=0-0172).
Comment
Although the role of the thymus in myasthenia gravis is uncertain, its removal is used as a treatment for the disease. Higher five-and 10-year survival and remission rates have been reported for patients who have undergone thymectomy than for computer-matched patients with myasthenia gravis who have not had the operation.1 7 The presence of AChR-bearing muscle-like cells in thymus culture"8 has suggested that the thymus AChR may act as a stimulus for antibody production, which is subsequently also directed against the neuromuscular junction AChR. Alternatively, the thymus may act as the source of B-lymphocytes or of helper lymphocytes responsible for the continued production of antibody by B-lymphocytes. Culture of thymus tissue showed evidence of synthesis of AChR antibody in one of four patients with myasthenia gravis studied, and two of five patients displayed synthesis of AChR antibody by thymic lymphocytes cultured after thymectomy. '9 Our failure to show a drop in serum antibody concentrations after thymectomy does not eliminate the possibility that the thymus acts as the source of either the antigen or the antibody. It implies that, by the time of thymectomy, the pathological process may be self-sustaining or the thymus may be an important source of antibody in only a few patients. Alternatively, an as yet unrecognised subpopulation of antibody may be affected by thymectomy, although total antibody concentrations may not be substantially altered. The lack of apparent relations between serum anti-AChR antibody concentrations in patients with myasthenia gravis and thymectomy and the severity and duration of the disease suggests that if anti-AChR antibodies are the principal pathogenic factor in the disease factors other than the total serum anti-AChR concentration contribute to severity. Immunological variables might include differences in anti-AChR specificity or affinity,2 in anti-AChR class or subclass effecting complement fixation or antigenic modulation, or in the contribution of cellular immune mechanisms.2' Neurophysiological variables that might contribute to differing responses to the same concentration of serum anti-AChR antibody in different patients include differences in the initial content of AChR and in the ability of muscle to regenerate AChR or postsynaptic membrane structure. Identification of such immunological or neurophysiological variables would aid understanding of the pathology of myasthenia gravis.
Introduction
Most day hospitals are for geriatric or psychiatric patients. We run a day hospital catering for patients with preterminal cancer and chronic disease, which has been developed (mainly through the generosity of the Nuffield Foundation) as an integral part of a terminal-care unit; and we discuss here its first 26 months.
The background
The 25-bed unit for patients with terminal cancer and the chronic sick is supported by an independent charity but most of the beds are financed by a contract with the area health authority. It takes 350-450 patients a year, mostly suffering from disseminated cancer; some 12% of the local cancer deaths occur in the unit, the average stay being
